Ankylosing spondylitis

Arévalo M et al. Arthritis Res Ther 2018; 20: 221. doi: 10.1186/s13075-018-1724-7

Watad A et al. Curr Rheumatol Rep 2018; 20: 41. doi: 10.1007/s11926-018-0751-3

Feld J et al. Nat Rev Rheumatol 2018; 14: 363–371. doi: 10.1038/s41584-018-0006-8

Miao J & Zhu P. Curr Rheumatol Rep 2018; 20(5): 30. doi: 10.1007/s11926-018-0729-1

Veale DJ et al. Rheumatology (Oxford) 2018; Advance online publication. doi: 10.1093/rheumatology/key070

Bodis G, Toth V, Schwarting A. Rheumatol Ther 2018; Advance online publication. doi: 10.1007/s40744-018-0100-z

Nat Rev Rheumatol 2018; 14: 170–180. doi: 10.1038/nrrheum.2018.17

The authors find that tumor necrosis factor-α inhibitors exert a mild effect on the gene expression of patients with ankylosing spondylitis, including genes considered to be a genetic signature of the disease.

Genes Immun 2017;18:184–190. doi:10.1038/gene.2017.19

The authors review the current knowledge of ankylosing spondylitis pathogenesis, including genetic risk associations, HLA-B27-mediated pathology, perturbations in antigen-presentation pathways, and the type 3 immune response.

Nat Rev Rheumatol 2017;13:359–367. doi:10.1038/nrrheum.2017.56

In this article, the authors briefly review the molecular mechanisms that lead to structural damage in ankylosing spondylitis and the impact of treatment with biologics to retard this process.

Magrey MN, Khan MA. Curr Rheumatol Rep 2017;19:17. doi:10.1007/s11926-017-0644-x

Bidad et al. discuss the types of pain experienced in ankylosing spondylitis, insights from brain imaging studies, neurological mechanisms of pain, sex bias in pain, and how the immune system can modify pain.

Nat Rev Rheumatol 2017;13:410–420. doi:10.1038/nrrheum.2017.92

In this review, the authors discuss three interconnected mechanisms that might be involved in the predilection of specific joints for developing specific forms of arthritis.

Nat Rev Rheumatol 2017;13:433–442. doi:10.1038/nrrheum.2017.96

This article explores the potential role of autophagy in the pathogenesis of ankylosing spondylitis as it affects the immune system and is implicated in several rheumatic disease processes.

Ciccia F & Haroon N. Clin Rheumatol 2016;35:1433–14363. doi:10.1007/s10067-016-3262-5

An overview of the future of ankylosing spondylitis genetics, including new developments in major histocompatibility complex (MHC) genetics, and progress in non-MHC genetics.

Nat Rev Rheumatol 2016;12:81–91. doi:10.1038/nrrheum.2015.133

A regulatory role of T helper 17 (Th17) cells has been proposed in psoriatic arthritis (PsA). This review discusses the contributing role of the interleukin (IL)-23/IL-17 axis in the pathogenesis of PsA.

Raychaudhuri SK, Saxena A, & Raychaudhuri SP. Clin Rheumatol 2015;34:1019–1023. doi:10.1007/s10067-015-2961-7

A review discussing our current understanding of the pathogenesis of bone changes in ankylosing spondylitis, plus potential treatment modalities to modify disease progression.

Haroon N. Clin Rheumatol 2015;34:1003–1007. doi:10.1007/s10067-015-2956-4